Literature DB >> 32526342

Trends in Incidence of Autoimmune Liver Diseases and Increasing Incidence of Autoimmune Hepatitis.

Mehul Lamba1, Jing Hieng Ngu1, Catherine A M Stedman2.   

Abstract

BACKGROUND & AIMS: Autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) are autoimmune liver diseases of unknown etiology. We studied trends in incidences of AIH, PBC, and PSC in a population-based prospective study Canterbury, New Zealand.
METHODS: We collected data on patients with AIH (n = 99), PBC (n = 26), or PSC (n = 47) from public hospitals and private practices in Canterbury from 2008 through 2016. Diagnoses were made based on international standardized criteria. We calculated incidence rates for the time periods of 2008-2010, 2011-2013, and 2014-2016 and compared them using 2-tailed mid-P exact tests.
RESULTS: Overall incidence rates were 1.93 per 100,000 for AIH (95% CI, 1.58-2.34), 0.51 per 100,000 for PBC (95% CI, 0.33-0.73), and 0.92 per 100,000 for PSC (95% CI, 0.68-1.21). The incidence of AIH was significantly higher during the period of 2014-2016 (2.39 per 100,000; 95% CI, 1.76-3.23) than during the period of 2008-2010 (1.37 per 100,000; 95% CI, 0.91- 2.06) (P < .05). Incidences of PBC and PSC did not change significantly. In 2016, prevalence values were 27.4 per 100,000 for AIH (95% CI, 23.58-32.0), 9.33 per 100,000 for PBC (95% CI, 7.13-12.05), and 13.17 per 100,000 for PSC (95% CI, 10.56-16.42).
CONCLUSIONS: In a population-based prospective study, we found that the incidence of AIH was significantly higher in the 2014-2016 period than the 2008-2010 period; incidences of PBC and PSC were unchanged over the same period. Further studies are needed to determine the reasons for changes in incidence of autoimmune liver diseases.
Copyright © 2021 AGA Institute. All rights reserved.

Entities:  

Keywords:  Autoimmune Hepatitis; Autoimmune Liver Disease; Epidemiology; Primary Biliary Cholangitis; Primary Sclerosing Cholangitis

Year:  2020        PMID: 32526342     DOI: 10.1016/j.cgh.2020.05.061

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  6 in total

1.  Outcomes of pregnancy in autoimmune hepatitis: A population-based study.

Authors:  Connie W Wang; Joshua Grab; Michele M Tana; Roxanna A Irani; Monika Sarkar
Journal:  Hepatology       Date:  2021-12-05       Impact factor: 17.298

2.  Presence of Serum Antinuclear Antibodies Does Not Impact Outcomes in HBV-Related Acute-on-Chronic Liver Failure.

Authors:  Lin Lin; Bin Lin; Qing Lan; Longgen Liu; Jianchun Lu; Xiujun Zhang; Shuqin Zheng; Yuan Xue
Journal:  Can J Gastroenterol Hepatol       Date:  2022-02-18

Review 3.  Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice.

Authors:  Federica Invernizzi; Marta Cilla; Silvia Trapani; Maria Guarino; Valentina Cossiga; Martina Gambato; Maria Cristina Morelli; Filomena Morisco; Patrizia Burra; Annarosa Floreani
Journal:  J Pers Med       Date:  2022-06-02

4.  Intrahepatic activated leukocyte cell adhesion molecule induces CD6highCD4+ T cell infiltration in autoimmune hepatitis.

Authors:  Qiwei Qian; Nana Cui; Bingyuan Huang; Yudong Zhao; Qiaoyan Liu; Mingli Hu; Bo Li; Qixia Wang; Qi Miao; Zhengrui You; Xiong Ma; Ruqi Tang
Journal:  Front Immunol       Date:  2022-09-09       Impact factor: 8.786

5.  Type 2 Autoimmune Hepatitis and Nonadherence to Medication Correlate With Premature Birth and Risk of Postpartum Flare.

Authors:  Kathryn Olsen; James Hodson; Vincenzo Ronca; Amber G Bozward; Jennifer Hayden; Grace Wootton; Matthew Armstrong; David H Adams; Omar El-Sherif; James Ferguson; Ellen Knox; Tracey Johnston; Fiona Thompson; Ye Htun Oo
Journal:  Hepatol Commun       Date:  2021-05-21

6.  The Epidemiology of UK Autoimmune Liver Disease Varies With Geographic Latitude.

Authors:  Gwilym J Webb; Ronan P Ryan; Tom P Marshall; Gideon M Hirschfield
Journal:  Clin Gastroenterol Hepatol       Date:  2021-01-22       Impact factor: 11.382

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.